Compare American Airlines Group Inc (AAL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Incyte Corporation — how do they compare? American Airlines Group Inc trades at $14.99 (market cap $10.55B), while Incyte Corporation trades at $120.68 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 2.3× American Airlines Group Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | INCY | |
|---|---|---|
Market Cap | $10.55B | $24.54B |
Sector | Industrials | Health |
52-Week High | $18.15 | $129.93 |
52-Week Low | $10.18 | $81.61 |
Enterprise Value | $38.51B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $15.06, up 0.37% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported mixed Q2 2026 results with revenue growth but faces margin pressure from fuel costs. Analyst consensus is a Buy with a $19.63 price target, though high debt and volatile profitability remain concerns.
AAL offers potential upside from its discounted valuation and premium revenue recovery, but investors face risks from fuel price volatility, high leverage, and competitive pressures. The stock's outlook hinges on sustained travel demand and cost management amid economic uncertainty.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
